Saiyun Bio Secures Tens of Millions in Angel Funding to Advance Novel Drug Delivery Platform

VCBeat has learned that Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as “Saiyun Biotech”) recently announced good news: the company has successfully completed an angel financing round worth tens of millions of yuan, led byLSV CAPITALCo-led the investment with a renowned fund,Inno Angel Fund, among other entities, participated in co-investment.

Saiyun Biotechnology is dedicated to developing cutting-edge international delivery vector technologies and related innovative drug therapies, aiming to provide a novel approach for precise drug delivery. With the approval and market launch of cell and gene therapies as well as gene-editing drugs, bioactive molecules are becoming increasingly complex, necessitating more precise and advanced delivery systems to match them. An ideal delivery system should not only protect the drug payload but also accurately transport it to the appropriate cells, tissues, organs, or compartments within the body, thereby minimizing off-target effects and enhancing safety.

Saiyun Biotechnology has developed a Class I natural delivery system that can be rationally engineered to directly deliver various types of payloads, such as functional biological macromolecules, into specific cells. This delivery system offers advantages including high specificity in cell recognition, high compatibility and protection for the payload, and low production costs.

Currently, Saiyun Biotechnology’s R&D laboratory has been established in the Zhongguancun Life Science Park in Beijing, boasting a research and process development team of over ten members. Its core technical personnel hold doctoral degrees from prestigious institutions both domestically and abroad, and possess extensive experience in both industry and academia. Leveraging the park’s comprehensive platform and complete industrial chain support services, Saiyun Biotechnology has developed multiple pipelines in fields such as tumor-targeted therapy and cell and gene therapy. Efficacy and safety testing of related drug delivery systems, as well as optimization of manufacturing processes, are currently underway.

Saiyun Biotechnology Laboratory

The success of this financing round will provide strong support for the development of Saiyun Biotechnology. Meanwhile, through amicable communication and collaboration with leading domestic research institutions and large Grade-A tertiary hospitals, the company is poised to achieve greater breakthroughs in key areas such as the development of novel delivery vectors and pipeline advancement. This will lay a solid foundation for subsequent investigator-initiated clinical trials and Investigational New Drug (IND) applications, thereby bringing more innovative surprises to the field of novel biopharmaceuticals and contributing further to the health and well-being of patients worldwide.

Regarding this round of financing,Dr. Jiang Feng, Co-founder of Saiyun BiotechnologyStatement: We extend our sincere gratitude to the investors for their support. Drug delivery has long been the most critical bottleneck in realizing precision medicine. Currently, there is a substantial unmet medical need due to the delivery challenges associated with both small-molecule and macromolecular drugs. Saiyun Biotechnology is an innovative biotech company focused on targeted protein and nucleic acid delivery therapies. Leveraging its novel drug delivery technology platform, the company is poised to pioneer new directions in the field of drug delivery and continue contributing to the enhancement of China’s new quality productive forces.

Life Science Park Venture Capital Fund"Novel drug delivery systems will bring about fundamental transformative innovation to innovative therapies, representing a key strategic focus for LSV CAPITAL. We are optimistic about Saiyun Biotechnology’s significant potential to lead continuous progress in this field, and we recognize Professor Jiang Feng’s profound scientific accumulation in this technology platform over the years. Having witnessed Saiyun Biotechnology’s incubation and growth within the LSV CAPITAL shared space, we hold high expectations for its future."

Zhu Xiaocheng, Managing Partner of Innocore Angel FundIt was stated that the Saiyun team possesses a proprietary delivery technology platform capable of delivering multiple categories of therapeutics, including proteins, cytokines, and delivery tools, thereby meeting the diverse delivery requirements of various treatments. Innocore has been actively exploring and strategically positioning itself in innovative therapies. As delivery tools are a critical component in enhancing therapeutic efficacy, Saiyun’s portfolio of efficient, high-capacity, and low-cost delivery vectors will facilitate the clinical application of more advanced and effective treatment technologies, ultimately benefiting patients.

The Life Science Park Venture Capital Fund is a specialized fund led by Zhongguancun Development Group’s Lingchuang Investment and Zhongguancun Capital. With the Beijing Science and Technology Innovation Center and Zhongguancun Life Science Park as its primary incubation bases, the fund provides professional investment and financing services for technological innovation, with a reach extending across China.

LSV CAPITAL is driven by the vision of “discovering scientists and entrepreneurs who change the world, and jointly creating tangible social value.” Its investment portfolio spans biopharmaceuticals, high-end medical devices, synthetic biology, and other sectors. The firm has invested in healthcare technology companies including Yanming Biologics, Huayi Lejian, Vitaron, Huaxia Yingtai, Molecule Mind, Binuozhi, Weigong Technology, and Zhitai Bio.

Inno Angel Fund was established in April 2013. With billions of RMB under management, it has invested in over 500 innovative projects to date. Its investment management team boasts an average of more than 10 years of angel investment experience. Building on its foundation among Tsinghua University alumni, the fund has developed a multi-dimensional startup service ecosystem. Committed to becoming a self-evolving, innovative angel investment platform, Inno Angel Fund adheres to the investment philosophy of “Investing in Innovation, Achieving Mutual Success.” It has deeply cultivated and strategically laid out its presence in major entrepreneurial hubs, including Beijing, the Yangtze River Delta, Central and Western China, the Guangdong-Hong Kong-Macao Greater Bay Area, and Silicon Valley in the United States. By establishing a cross-regional investment and startup service network, the fund achieves high investment efficiency and rapid returns.

Inno Angel Fund focuses on next-generation information technology, new energy and new materials, life sciences, and advanced manufacturing. It primarily invests in the angel and Pre-A stages. Over 80% of Inno’s portfolio companies have secured subsequent funding rounds, with multiple companies initiating IPOs. Since its establishment, the fund has consistently been honored as one of the “Top 10 Early-Stage Investment Institutions in China.”